Spark Therapeutics Inc. (NASDAQ:ONCE) shares saw unusually-strong trading volume on Friday . Approximately 688,699 shares were traded during mid-day trading, an increase of 60% from the previous session’s volume of 430,840 shares.The stock last traded at $57.53 and had previously closed at $57.55.

A number of equities analysts have recently weighed in on ONCE shares. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. Wedbush reaffirmed an “underperform” rating and issued a $21.00 price target on shares of Spark Therapeutics in a research note on Thursday, May 19th. SunTrust Banks Inc. upped their price target on shares of Spark Therapeutics from $64.00 to $72.00 and gave the stock a “buy” rating in a research note on Tuesday, June 21st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $94.00 price target (down from $100.00) on shares of Spark Therapeutics in a research note on Thursday, June 23rd. Finally, Royal Bank Of Canada started coverage on shares of Spark Therapeutics in a research note on Tuesday, July 12th. They issued an “outperform” rating and a $70.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. Spark Therapeutics presently has an average rating of “Hold” and an average target price of $62.27.

The stock’s 50 day moving average price is $56.97 and its 200-day moving average price is $44.90. The stock’s market capitalization is $1.78 billion.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.07. The firm had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.17 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the company posted ($0.60) earnings per share. On average, equities analysts predict that Spark Therapeutics Inc. will post ($3.96) EPS for the current fiscal year.

In related news, CEO Jeffrey D. Marrazzo sold 5,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $46.49, for a total value of $232,450.00. Following the sale, the chief executive officer now directly owns 235,000 shares of the company’s stock, valued at approximately $10,925,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Hospital Of Philade Children’s sold 1,000,000 shares of the business’s stock in a transaction on Monday, June 20th. The shares were sold at an average price of $42.30, for a total transaction of $42,300,000.00. Following the completion of the sale, the insider now directly owns 6,768,707 shares in the company, valued at $286,316,306.10. The disclosure for this sale can be found here.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.